
Apogossypol
CAS No. 66389-74-0
Apogossypol( +)-Apogossypol | NSC 736630 )
Catalog No. M15530 CAS No. 66389-74-0
Apogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 1053 | Get Quote |
![]() ![]() |
50MG | 2142 | Get Quote |
![]() ![]() |
100MG | 2790 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameApogossypol
-
NoteResearch use only, not for human use.
-
Brief DescriptionApogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively.
-
DescriptionApogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively; induces apoptosis of tumor cell lines, inhibits the growth and proliferation of prostate cancer cells by downregulating Bcl?2 protein expression and activating caspase?3 and ?8; displays superior activity to gossypol in terms of reducing splenomegaly and reducing B-cell counts in spleens of Bcl-2-transgenic mice.
-
In VitroIn agreement with NMR binding and fluorescence polarization assays (FPAs) data, (+)-Apogossypol displays potent binding affinity to Bcl-xL with Kd values of 1.7 μM.To investigate the inhibitory effects of (+)-Apogossypol and Gossypol on LNCaP cell survival, the MTT assay is performed. The results demonstrate that (+)-Apogossypol inhibits the proliferation of LNCaP cells in a time- and dose-dependent manner, in a similar way with Gossypol. The concentration for 50% inhibition (IC50) on LNCaP cells within ~72 h is 9.57 μM, while the IC50 of Gossypol on LNCaP cells is 10.35 μM.
-
In VivoDue to its modified structure, (+)-Apogossypol is expected to exhibit lower toxicity while maintaining the significant anti-growth and anti-tumor activities in vitro, similar to those of Gossypol. The anti-cancer effect of (+)-Apogossypol is evaluated in mice bearing subcutaneous LNCaP cell xenografts. The tumor growth is monitored and measured by a caliper and balance. The survival rate of the mice is notably improved by (+)-Apogossypol. Of note, the tumor sizes are also markedly decreased by (+)-Apogossypol treatment (P<0.01).
-
Synonyms+)-Apogossypol | NSC 736630
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number66389-74-0
-
Formula Weight462.53
-
Molecular FormulaC28H30O6
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC1=CC2=C(C(=C(C=C2C(=C1C3=C(C4=CC(=C(C(=C4C=C3C)C(C)C)O)O)O)O)O)O)C(C)C
-
Chemical Name[2,2'-Binaphthalene]-1,1',6,6',7,7'-hexol, 3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2S)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Becattini B, et al. Chem Biol. 2004 Mar;11(3):389-95.
2. Wei J, et al. Mol Cancer Ther. 2009 Apr;8(4):904-13.
3. Kitada S, et al. Blood. 2008 Mar 15;111(6):3211-9.
4. Zhan W, et al. Mol Med Rep. 2015 Jun;11(6):4142-8.
molnova catalog



related products
-
Isoverticine
Isoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.
-
UMI-77
A potent and selective Mcl-1 inhibitor with Ki of 0.49 uM; displays >10 fold selectivity against Bcl-w, Bfl-1, Bcl-xL and Bcl-2.
-
BXI-72
BXI-72 (NSC334072, Hoechst 33342) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM).